LENSAR

LNSR

Market cap $149M

Overview Fund Activity

12.47 USD

+0.34

2.8%

At close Updated Sep 12, 4:00 PM EDT

1 day

2.8%

5 days

1.88%

1 month

-3.48%

3 months

-0.24%

6 months

-18.71%

Year to date

43.5%

1 year

148.41%

5 years

38.56%

10 years

38.56%

About: LENSAR Inc is a commercial-stage medical device company focused on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts. The company Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, simplified procedure planning, efficient design, and precision. Its product portfolio consists of the LENSAR Laser System with Streamline IV and IntelliAxis and its associated consumable components. Geographically, the company generates the majority of its revenue from the United States, followed by Europe and Asia.

Employees: 140

Healthcare Medical Devices

0

Funds holding %

of 7,462 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

133% more repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 12

120% more call options, than puts

Call options by funds: $716K | Put options by funds: $326K

59% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 17

15% more funds holding

Funds holding: 66 [Q1] → 76 (+10) [Q2]

5% more capital invested

Capital invested by funds: $56.9M [Q1] → $60M (+$3.01M) [Q2]

4.71% more ownership

Funds ownership: 33.91% [Q1] → 38.62% (+4.71%) [Q2]

See Fund Rankings

Financial journalist opinion

LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ORLANDO, Fla., Sept. 02, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”) today announced that a majority of the independent members of LENSAR's board of directors granted three newly-hired non-executive employees an aggregate of 660 restricted stock units (“RSUs”).

LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

The Motley Fool

Lensar (LNSR) Q2 Revenue Rises 10%

Lensar (LNSR) Q2 Revenue Rises 10%

Lensar (LNSR) Q2 Revenue Rises 10%

LENSAR Reports Second Quarter 2025 Results and Provides Business Update

18 ALLY Robotic Cataract Laser Systems™ (“ALLY Systems”) placed in 2Q 2025 with an additional backlog of 18 ALLY Systems pending installation as of June 30, 2025

LENSAR Reports Second Quarter 2025 Results and Provides Business Update

LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ORLANDO, Fla., July 01, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”) today announced that a majority of the independent members of LENSAR's board of directors granted three newly-hired non-executive employees an aggregate of 660 restricted stock units (“RSUs”). The RSUs were granted as of July 1, 2025, as inducement for each such employee commencing employment with the Company. The RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LENSAR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of LENSAR, Inc. - LNSR

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of LENSAR, Inc. (NasdaqCM: LNSR) to Alcon Inc. (NYSE: ALC). Under the terms of the proposed transaction, shareholders of LENSAR will receive $14.00 in cash, with an additional non-tradeable contingent value right offering up to $2.75 per share in cash conditioned on achievement of a milestone, for each.

LENSAR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of LENSAR, Inc. - LNSR

LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ORLANDO, Fla., June 02, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”) today announced that a majority of the independent members of LENSAR's board of directors granted 10 newly-hired non-executive employees an aggregate of 3,090 restricted stock units (“RSUs”). The RSUs were granted as of June 2, 2025, as inducement for each such employee commencing employment with the Company. The RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LENSAR Reports First Quarter 2025 Results and Provides Business Update

14 ALLY Robotic Laser Cataract Systems™ (“ALLY Systems”) placed in 1Q 2025 with an additional backlog of 24 systems pending installation as of March 31, 2025

LENSAR Reports First Quarter 2025 Results and Provides Business Update

LENSAR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of LENSAR, Inc. - LNSR

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of LENSAR, Inc. (NasdaqCM: LNSR) to Alcon Inc. (NYSE: ALC). Under the terms of the proposed transaction, shareholders of LENSAR will receive $14.00 in cash, with an additional non-tradeable contingent value right offering up to $2.75 per share in cash conditioned on achievement of a milestone, for each.

LENSAR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of LENSAR, Inc. - LNSR

Zacks Investment Research

ALC Stock Rises Following the Merger Agreement With LENSAR

Alcon enters into a definitive merger agreement to acquire LENSAR's ALLY Robotic Cataract Laser Treatment System, proprietary Streamline software technology and LENSAR legacy laser system.

ALC Stock Rises Following the Merger Agreement With LENSAR

$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of LENSAR, Inc. - LNSR

NEW YORK , March 24, 2025 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating LENSAR, Inc. (NASDAQ: LNSR ), relating to the proposed merger with Alcon.

$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of LENSAR, Inc. - LNSR

See News Rankings

Charts implemented using Lightweight Charts™